Hematopoietic stem cells (HSCs) are the source of all blood components, and genetic defects in these cells are causative of disorders ranging from severe combined immunodeficiency to sickle cell disease. However, genome editing of long-term repopulating HSCs to correct mutated alleles has been challenging. HSCs have the ability to either be quiescent or cycle, with the former linked to stemness and the latter involved in differentiation.
Introduction
Hematopoietic stem cells (HSCs) ensure the lifelong production of all blood cells through their unique capacity to self-renew and to differentiate ( Figure 1A ). Deficiencies in HSC renewal lead to severe anemias such as Fanconi Anemia and Diamond Blackfan Anemia (Corey et al., 2007) . Inappropriate differentiation can lead to either the over-or under-production of blood components, causing disorders that range from immunodeficiency to cancer.
Due to their ability to simultaneously self-renew and generate the entire blood system, long-term HSCs represent an attractive target for gene therapy and editing to deliver lasting treatments for blood disorders. Genome editing, most recently accelerated by the development of CRISPR-Cas reagents, has emerged as an effective tool to precisely target human HSCs (Dever et al., 2016; DeWitt et al., 2016; Genovese et al., 2014b; Hoban et al., 2015; De Ravin et al., 2017; Wang et al., 2015) . However, the replacement of genetic sequences via nucleaseinduced HDR in HSCs has lagged behind the ability to disrupt sequences via NHEJ.
Specifically, while bulk-edited CD34+ populations of HSPCs exhibit high levels of HDR after a few days in culture, sustained engraftment of HDR-edited cells in the Long-Term engrafting HSPCs have been shown to primarily consist of cells that preserve the potential to engraft (Masiuk et al., 2017; Zonari et al., 2017) . Using the timed administration of a small molecule cocktail originally developed for HSC maintenance, we developed a protocol to place HDRedited EE HSPCs back into quiescence. The end result is G0 EE HSPCs whose HDR editing efficiency reflects the rest of the CD34+ HSPC population. This translates to an almost 6-fold increase in HDR/NHEJ ratios of EE HSPCs. These data yield new insights into the DNA repair preferences of HSPCs enriched for engrafting cells and suggests routes to therapeutic protocols for efficient genome editing to cure blood disorders.
Results

HSCs require more time to activate HDR pathways during gene editing as compared to differentiated cells
While gene editing reagents have been used to induce significant levels of HDR editing in bulk CD34+ HSPCs, maintenance of HDR for a prolonged period of time after in vivo engraftment has been challenging (Dever et al., 2016; DeWitt et al., 2016; Genovese et al., 2014b; Hoban et al., 2015; Wang et al., 2015) . By contrast, NHEJ is maintained at high levels during prolonged engraftment. This could either arise because the act of editing somehow makes LT-HSCs lose markers of stemness, or because LT-HSCs do not perform HDR. To address this dichotomy, we first interrogated the extent to which primitiveness affects the repair decision after a Cas9-induced DSB in human mPB CD34+ HSPCs.
We utilized a potent single guide RNA (sgRNA) we previously found to efficiently edit human CD34+ HSPCs at the HBB locus and an ssODN donor template designed to modify the causative hemoglobin beta (HBB) mutation involved in sickle cell disease (SCD) ( Figure S1A ) (Cradick et al., 2013; DeWitt et al., 2016) . After editing bulk CD34+ HSPCs, we measured the efficiency of HDR and NHEJ in immunophenotypically sorted HSCs (CD34+ CD38-CD45RA-CD90+), MPPs (CD34+ CD38-CD45RA-CD90-), and progenitors (CD34+ CD38+) (Figures 1A and 1B) . Editing efficiency was quantified by using next-generation amplicon sequencing encompassing the HBB target site ( Figure S1B ).
We cultured CD34+ HSPCs in stem cell expansion media consisting of SFEMII and CC110 cytokine cocktail (SC) for one day, electroporated the cells with HBB-targeting Cas9 ribonucleoprotein complexes (RNPs) and cultured the HSPCs for one day before separating several HSPC subsets using fluorescence-activated cell sorting (FACS) and assessing the editing efficiency in each subset through NGS genotyping (Figure 1C top) . Both HDR and NHEJ were evident in bulk CD34+ cells and relatively differentiated progenitors (CD34+ CD38+). Total editing was somewhat reduced in MPPs (CD34+ CD38-CD45RA-CD90-). Strikingly, we found moderate amounts of NHEJ in immunophenotypic HSCs (CD34+ CD38-CD45RA-CD90+) but almost no HDR in these cells, which led to a 3-fold lower HDR/NHEJ ratio in HSCs compared to bulk CD34+ HSPCs. ( Figure 1C ).
We further cultured the sorted populations (HSCs, MPPs, and progenitors) and found that HSCs eventually accumulated HDR edits, but only 72 hours after electroporation ( Figure   S1C ). However, the HDR/NHEJ ratio was highest in progenitors and lowest in HSCs even 72 hours after electroporation ( Figure S1C ). In contrast, keeping CD34+ HSPCs in culture for two days before electroporation led to the appearance of significant HDR edits just one day after electroporation ( Figure 1D ). HDR was evident in all HSPC subtypes, including HSCs. These data indicate that more primitive HSCs preferentially repair Cas9-induced DSBs via NHEJ, but additional time in culture prior to the introduction of a DSB activates pathways related to HDR.
Establishing the timing of cell cycle status in CD34+ subsets during ex vivo culture HSPC primitiveness is linked to slower entry into the cell cycle (Laurenti et al., 2015) as well as lower frequency of cell cycle (Bradford et al., 1997; Morrison and Weissman, 1994; Pietrzyk et al., 1985; Suda et al., 1983; Uchida et al., 2003) , and cell cycle progression is a major hallmark of increasing time in culture for HSPCs. Since HDR is intimately linked with cell cycle, we hypothesized that HSCs cannot utilize HDR at short culture time points due to quiescence resulting from slow entry into the cell cycle.
While the cycling properties of freshly isolated mouse and human HSC subpopulations have been described (Benveniste et al., 2010; Cheshier et al., 1999; Copley et al., 2012; Foudi et al., 2009; Laurenti et al., 2015; Oguro et al., 2013; Passegué et al., 2005; Qiu et al., 2014; Wilson et al., 2008) , the cycling properties of human CD34+ HSPCs during extended ex vivo culture are not fully established. Before investigating the relationship between cell cycle status and editing efficiency, we first explored the cell cycle progression of CD34+ cells in ex vivo culture using immunophenotyping combined with Hoechst 33342 (stains for DNA) and Ki67 (highly expressed in proliferating cells) staining. (Gerdes et al., 1984; Kim and Sederstrom, 2015) . We found that more than 50% of cryopreserved mPB CD34+ HSPCs are quiescent (in G0) when thawed, but they gradually enter the cell cycle and are fully cycling by 3 days in SC culture (Figures 2A,2B , and S2).
We next examined CD34+ CD38-HSPCs, which contain most of the engraftment potential within the CD34+ population and are enriched for primitive populations such as HSCs and MPPs, as well as the more differentiated progenitor CD34+ CD38+ populations. For simplicity, here we define CD34+ CD38-HSPCs as "engraftment-enriched" (EE) HSPCs. Figures 2C, 2D , and S2). These results support the absence of HDR in quiescent cells and correlate with the vast difference in HDR efficiency between HSCs and progenitors ( Figure   1C ). By contrast, when cells are edited after two days in culture ( Figure 1D ), more than 50% of the EE HSPCs have begun to actively cycle. This could account for the significant amount of HDR observed in HSCs during longer ex vivo culture ( Figures 1D, 2C , and 2D).
Quiescent CD34+ HSPCs perform only NHEJ but cycling CD34+ HSPCs perform both
NHEJ and HDR.
To directly test how cell cycle status affects editing of human adult stem cells, we edited CD34+ HSPCs after one day in culture, allowed them to resolve edits for another day in culture, sorted them by cell cycle status, and used amplicon NGS to assess each population's editing outcomes ( Figure 3A top, Figure S3A ). One day after editing we found that cells in G1 and S-G2-M stages had a substantial amount of HDR alleles, but quiescent G0 CD34+ HSPCs almost completely lacked HDR alleles and had 3-fold decrease in HDR/NHEJ ratio compared to cycling HSPCs ( Figure 3A) . We observed NHEJ alleles in significant amounts regardless of cell cycle, though the highest amount was observed in the S-G2-M population ( Figure 3A) . Intriguingly, six hours after editing we found small amounts of NHEJ alleles across various cell cycle subpopulations, but HDR alleles do not appear in any of the cell cycle subpopulations, consistent with reports from other cell types that HDR takes longer than NHEJ (Arnoult et al., 2017; Mao et al., 2008) (Figure S3B ).
We next asked whether additional time in culture altered CD34+ HSPC editing outcomes according to cell cycle status. Since Hoechst staining led to a significant decrease in viability in CD34+ HSPCs ( Figure S3C and S3D), we developed a live cell staining protocol that utilizes Pyronin Y that can stain both DNA and RNA when used alone (Darzynkiewicz et al., 1987 (Darzynkiewicz et al., , 2004 . Cells were cultured for two days, then edited and immediately subjected to a live cell cycle sort using Pyronin Y accumulation ( Figure 3B top and Figure S3E ). Sorted subpopulations were cultured for an additional 2 days before NGS genotyping in order to allow edits to resolve according to cell cycle status ( Figure 3B Since almost all CD34+ cells exit quiescence within three days in culture (Figure 2 ), CD34+ HSPCs that are still in G0 at the time of editing (mostly CD34+ CD38-EE HSPCs) should exit quiescence by the end of a long culture and would be able to accumulate significant HDR alleles while cycling. Hence, our results overall suggest that non-cycling CD34+ HSPCs in G0 are highly enriched in primitive EE HSPCs and heavily rely on the NHEJ pathway as opposed to HDR. By contrast, cycling cells in G1 and S-G2-M are enriched in more differentiated CD34+ CD38+ progenitors and utilize both HDR and NHEJ.
Preventing exit from quiescence blocks HDR repair in CD34+ HSPCs
Our previous experiments showed that quiescent, primitive HSPC subsets are less likely to perform HDR than cycling, differentiated subsets. We next tested whether induction of quiescence was sufficient to affect HDR levels under otherwise HDR-competent conditions. We induced quiescence using either retinoic acid, which has been shown to drive mouse HSCs into deep dormancy (Cabezas-Wallscheid et al., 2017) , or inhibitors of mTOR (Rapamycin) and GSK-3 (CHIR9901), which have been used to maintain mouse and human HSCs ex vivo and in vivo (Huang et al., 2012) (Figure S3F ). We found that treatment of CD34+ HSPCs with retinoic acid in SC media led to differentiation as measured by substantial loss of CD34 expression which could potentially be due to the differences in maintenance of HSCs in mouse and human, whereas a combination of Rapamycin and CHIR99021 in X-VIVO media (XRC) led to the prevention of cell cycle entry while maintaining primitiveness ( Figure S3F -H).
We investigated editing outcomes in CD34+ HSPCs cultured in XRC media as compared to SC expansion media. We used three different treatment regimens ( Figure 3C ).
One set of HSPCs was kept in SC both before and after editing. A second set was started in XRC before editing, and then either maintained in XRC after editing or moved to SC after editing. All cells were sorted based on cell cycle and editing outcomes for each stage of the cell cycle were measured by NGS. Cells maintained in SC media entered cell cycle as normal, exhibiting a decrease in G0 cells and increase in G1 and S-G2-M cells after three days. Pretreatment of CD34+ HSPCs with XRC media led to the prevention of cell cycle entry, with almost all cells in G0 after three days ( Figure 3D ). Treatment with XRC was not associated with a decrease in cell viability ( Figure 3E ), and moving XRC-treated cells to SC media allowed HSPCs to re-enter the cell cycle, as measured by a decrease in G0 cells and increase in G1 and S-G2-M. (Figure 3D ). Strikingly, quiescent CD34+ HSPCs treated continuously with XRC repaired almost all Cas9-induced DSBs using NHEJ and harbored almost undetectable levels of HDR alleles.
Moving XRC-treated HSPCs to SC media after editing led to increased levels of HDR, but this was mostly confined to cells in G1 and S-G2-M. HSPCs maintained in SC before and after editing exhibited low levels of HDR in G0 cells, but high levels of HDR in G1 and S-G2-M (Figures 3F). These results show that small molecule-induced quiescence in HSPCs is sufficient to prevent HDR even after multiple days in ex vivo culture, and that cycling is necessary for high levels of HDR.
Inducing quiescence after a short period of cycling yields quiescent, primitive HSPCs that harbor HDR alleles
While XRC treatment has previously been used to maintain stemness (Huang et al., 2012) , we next asked whether these compounds could induce quiescence after HSPCs have been allowed to cycle. Our overall goal was to allow HSPCs to cycle to accumulate HDR alleles during editing, and then to place them back into G0 in order to maintain stemness.
We edited CD34+ HSPCs and cultured them in SC media to allow them to enter the cell cycle ( Figure 4A ). On the day of electroporation, 50% of CD34+ HSPCs were quiescent as expected ( Figure S4A ). Two days after editing we sorted cells based on cell cycle and quantified editing outcomes by NGS. We found that at this timepoint most cells had exited G0 and were in G1 or S-G2-M ( Figure 4B ) although less of EE HSPCs were in S-G2-M compared to the progenitors ( Figure S4B ). As before, HDR alleles were almost completely absent from the remaining G0 cells but present in G1 and S-G2-M cells, while NHEJ alleles were present in all stages of the cell cycle ( Figure 4C ). HDR/NHEJ ratio was 7 times lower in G0 cells than G1 and S-G2-M cells. We then kept the remaining HSPCs in SC to allow cycling to continue for another three days, or moved them to XRC to induce quiescence. Six days after editing (three days in SC and three additional days in either SC or XRC), we sorted based on cell cycle and quantified repair outcomes by NGS.
HSPCs that were maintained continuously in SC media were almost completely lacking in G0 cells by six days after editing ( Figure 4D ). The remaining cells, which were only in G1 or S-G2-M, harbored high levels of HDR alleles ( Figure 4E ). By contrast, cells moved to XRC media had almost 40% G0 cells and relatively few cells in S-G2-M ( Figure 4D ). Notably, 60% of the primitive EE HSPCs returned to quiescence as compared to 30% of CD34+38+ progenitors ( Figure S4E ). We found that the G0 cells in XRC now harbored high levels of HDR alleles, and were in fact comparable in HDR to G1 and S-G2-M cells ( Figure 4E ). We show that XRC treatment maintains stemness ( Figure S4C ) and supports viability ( Figure S4D ) and is distinctive from the omission of cytokines that generally leads to loss of CD34+ expression and viability ( Figure S4C and S4D). We further found that post-treatment with XRC led to enrichment in EE HSPCs (CD34+ CD38-markers of stemness) as compared to continued culture in SC ( Figure 4F ). In sum, we have developed a strategy to enable high efficiency HDR in immunophenotypically primitive and quiescent HSPCs. This strategy allows HSPCs to briefly cycle after Cas9-mediated induction of a DSB to allow HDR, and then places cells back into quiescence after HDR alleles have been acquired.
Discussion
Our data suggest a potential path towards the use of gene edited HSCs for therapeutic purposes, and also shed light on fundamental HSC biology. The DNA repair decisions after a double strand break in primitive human hematopoietic cells are essential for cell survival, yet are underexplored due to difficulties in studying human HSCs. Aged human hematopoietic cells shows elevated levels of unresolved DSBs and increased mutation frequencies, but the mechanisms underlying DSB repair in these cell types are largely unknown (Beerman et al., 2014; Genovese et al., 2014a; Rossi et al., 2007; Rübe et al., 2011; Weinstein et al., 2013 ).
Here we have used CRISPR genome editing to induce a precise DSB in mixed CD34+ HSPCs and measured its repair in various cell subtypes and phases of the cell cycle via a combination of FACS and NGS. This approach could broadly accelerate in-depth probing of DNA repair decisions in many different stem cell types.
We found that genome editing of CD34+ HSPCs leads to high levels of NHEJ in multiple cell subtypes, but that HDR is preferentially missing from more primitive quiescent cells.
Instead, HDR accumulates in relatively differentiated cells and immunophenotypically primitive cells that have exited quiescence. Several groups have reported that genome editing CD34+
HSPCs leads to high-efficiency HDR in relatively short term in vitro culture that drops dramatically during long term in vivo engraftment (Dever et al., 2016; DeWitt et al., 2016; Genovese et al., 2014b; Hoban et al., 2015; Wang et al., 2015) . This is true even with very different modalities of Cas9 (mRNA, recombinant protein), guide RNA (synthetic, AAVexpressed), and HDR donor (single stranded DNA, AAV6) (Dever et al., 2016; DeWitt et al., 2016; Genovese et al., 2014b; Hoban et al., 2015; Kim et al., 2014; Wang et al., 2015) . Our results suggest that the observed in vivo lack of HDR is caused not by an inability to target immunophenotypic LT-HSCs, but because the repopulating stem cells are in an inappropriate phase of the cell cycle to perform HDR.
Mechanistic investigations of DNA repair have established that HDR is preferentially active in the S/G2 stages of the cell cycle, probably to avoid deleterious telomere fusions that can occur if HDR is active during mitosis (Orthwein et al., 2014) . Stem cells, such as HSCs therefore represent a challenge in that they divide during self-renewal and differentiation, but their stemness is intricately linked to long-term quiescence (Ema et al., 2000; Morrison and Weissman, 1994; Suda et al., 1983) . Prolonged in vitro culture of HSCs leads to a loss of stemness, entry into the cell cycle, and poor engraftment (Morrison and Kimble, 2006; Wilson et al., 2008) . There is a therefore a fundamental tension between HDR editing and the maintenance of stemness via quiescence. LT-HSCs may need to lose a defining feature of their stemness in order to obtain HDR edits.
One might avoid HDR entirely and instead pursue NHEJ-based editing. This approach shows promise for the treatment of sickle cell disease, where disruption of various repressor elements leads to re-expression of protective fetal hemoglobin (Bauer et al., 2013; Bjurström et al., 2016; Canver et al., 2015; Chang et al., 2017) . NHEJ is well-represented in long-term engrafting HSCs during genome editing (Dever et al., 2016; DeWitt et al., 2016; Genovese et al., 2014b; Hoban et al., 2015; Wang et al., 2015) , and here we show via immunophenotyping and cell cycle analysis that HSCs in G0 are fully capable of accumulating NHEJ alleles.
However, limiting oneself to NHEJ-based editing does not fully tap the potential of genome editing. Many fundamental questions are best answered by surgically replacing genomic sequences, and relatively few genetic diseases can be cured by NHEJ-based sequence disruption.
We find that the drop in levels of HDR after long term CD34+ engraftment is reflected in poor HDR in the quiescent LT-HSC subpopulation. By contrast, cycling progenitor cells and even MPPs exhibit significant levels of HDR. Since HDR is maximal during S-G2 phase, we reasoned that progression through at least one cell cycle would be required for efficient HDR in HSCs (Branzei and Foiani, 2008; Hustedt and Durocher, 2017) . We show that allowing quiescent EE HSPCs to briefly enter the cell cycle enables HDR while retaining immunophenotypic markers representative of engraftment potential. We therefore allowed HSPCs to exit G0, edited them, allowed them to cycle, and only later added XRC to induce quiescence. This strategy results in quiescent EE HSPCs that exhibit more than 6-fold increases in HDR, close to those observed in cycling progenitors.
Directly addressing the tension between quiescent stemness and HDR is critical to fully achieve the potential of genome editing. Multiple types of stem cells potentially suffer from poor HDR that may be linked to quiescence (Bressan et al., 2017; Schwank et al., 2013; Urnov et al., 2010; Zhu et al., 2017) . It remains to be seen if the re-quiescence strategy we describe here will be applicable beyond HSCs, though one barrier is the paucity of culture models for various types of stem cells. Our data indicate that culture conditions can be just as important as editing modality to achieve desired genomic outcomes. See also Figure S1 . Representative data from n≥3 independent experiments with n≥2 biological replicates for each condition. Mean ± SD shown. **: p<0.01 by unpaired t-test.
(E) Editing outcomes in CD34+ cells 6 days in culture (3 days in SC media and 3 additional days in SC or XRC media). 3 days in XRC media results in HDR edits in G0 CD34+ HSPCs.
Representative data from n≥3 independent experiments with n≥2 biological replicates for each condition. Mean ± SD shown. See also Figure S4 .
STAR Methods
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by, the Lead Contact, jcorn@berkeley.edu
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cryopreserved wildtype human mobilized peripheral blood CD34+ HSPCs from multiple volunteer donors including male and female whose age ranged from 20-35 were purchased from Allcells, Inc.
METHOD DETAILS Primary Cell Culture
CD34+ HSPCs were cultured in SC (SFEMII + CC110 (StemCell Technologies)) media, XRC (X-VIVO15 (Lonza) + 5nM Rapamycin (EMD Millipore) + 3uM CHIR99021 (EMD Millipore)), or SC + 5uM All-trans retinoic acid (Sigma) media unless otherwise noted.
Electroporation for editing experiments
Cas9 RNP synthesis was carried out as previously described (Lin, Dewitt). Briefly, 75pmol of Cas9-NLS (UC Berkeley, Berkeley, CA) was mixed slowly into Cas9 buffer (20mM HEPES (pH 7.5), 150mM KCl, 1mM MgCl2, 10% glycerol and 1mM TCEP) containing 75pmol of synthetic sgRNA targeting the HBB locus (Synthego). The resulting 7.5ul mixture was incubated for 15minutes to allow RNP formation. 2x10 -5 CD34+ HSPCs were harvested, washed once with PBS, and resuspended in 20ul of P3 nucleofection buffer (Lonza, Basel, Switzerland). 7.5ul of RNP mixture and 20ul of cell suspension were combined and added into a Lonza 4d strip nucleocuvette and were electroporated with program ER-100. 200ul pre-warmed media was added to each nucleocuvette and electroporated cells were transferred to culture dishes. Editing outcomes were measured 1-5 days post-electroporation by Next Generation Amplicon
Sequencing.
PCR and Next-Generation Amplicon Sequencing preparation
50-100ng of genomic DNA from edited CD34+ cells was amplified at HBB sites using primer set 1 ( Figure S1A ). The PCR products were SPRI cleaned, followed by amplification of 20-50ng of the first PCR product in a second 12 cycle PCR using primer set 2 ( Figure S1A ). Then the second PCR products were SPRI cleaned, followed by amplification of 20-50ng of the second PCR product in a third 9 cycle PCR using illlumina compatible primers (primers designed and purchased through the Vincent J. Coates Genomics Sequencing Laboratory (GSL) at University of California, Berkeley), generating indexed amplicons of an appropriate length for NGS.
Libraries from 100-500 pools of edited cells were pooled and submitted to the GSL for pairedend 300 cycle processing using a version 3 Illumina MiSeq sequencing kit (Illumina Inc., San Diego, CA) after quantitative PCR measurement to determine molarity.
Next-Generation Amplicon Sequencing analysis
Samples were deep sequenced on an Illumina MiSeq at 300bp paired-end reads to a depth of at least 10,000 reads. A modified version of CRISPResso (Pinello et al., 2016 ) was used to analyze editing outcomes. Briefly, reads were adapter trimmed then joined before performing a global alignment between reads and the reference and donor sequences using NEEDLE (Li et al., 2015) . Rates of HDR are calculated as total reads that successfully convert the main (non-PAM out) edit site and have no insertions or deletions within three basepairs to each side of the cutsite divided by the total number of reads. NHEJ rates are calculated as any reads where an insertion or deletion overlaps the cutsite or occurs within three basepairs of either side of the cutsite divided by the total number of reads.
Immunofluorescence
Immunophenotypic analysis assays
Human CD34+ cells with or without editing were were first stained with fixable viability stain 660
(1:1000, BD) for 5 min in 37°C and then were stained with Percp-Cy5.5-anti-CD34 (1:50), PECy7-anti-CD38 (1:50), PE-anti-CD90 (1:30), FITC-anti-CD45RA (1:25), and BV421-anti-CD49f
(1:30) (all of the antibodies are from BD) for 30 min in 4°C. Samples were then sorted on Aria 
Fusion Cell Sorter (BD) or analyzed on LSR Fortessa cytometer (BD).
Cell cycle analysis assays
Apoptosis analysis assays (Annexin V, PI)
Human CD34+ cells with or without editing were first stained with Percp-Cy5.5-anti-CD34 (1:50) and PE-Cy7-anti-CD38 (1:50) for 30 min in 4°C before they were washed twice with BioLegend's Cell Staining Buffer (Biolegend) and stained with FITC Annexin V (Biolegend, 1:20) and PI (Biolegend, 1:10) for 15 minutes at room temperature. Then 400ul of Annexin V binding buffer was added and the samples were analyzed by LSR Fortessa cytometer (BD).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed with GraphPad Prism (version 7.00 for Mac, GraphPad Software) using unpaired two-tailed t-test analysis. Representative data from n≥2 independent experiments are shown in the figures unless otherwise stated. Each experiment included n≥2 biological replicates unless otherwise noted. More detailed information of experimental replicates are given in the figure legends of the corresponding experiments.
All values are given in the text as mean (±SD) and a p value < 0.05 was accepted as significant in all analyses, unless otherwise stated.
DATA AND SOFTWARE AVAILABILITY
The GEOS accession numbers for the next-generation sequencing data reported in this paper are ### (To be added). Proportion of CD34+ CD38-(normalized to SC SC)
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